Based on these promising experimental results, the α7 nAChR has been proposed as a potential target for managing schizophrenia [85,109], and α7-selective agonists and allosteric modulators have been tested in small-scale trials for the treatment of schizophrenia [110,111]. Here, IGKV2D-24 is linked to schizophrenia.